Hatteras Venture Partners Announces First Closing of HVP VI
First closing of $94 million in $200 million target size fund
New additions to and promotions within investment team
Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners VI, LP (HVP VI), with $94 million in deployable capital toward an ultimate target fund size of $200 million.
“The pace and quality of our deal flow has grown tremendously during the past several years,” said Clay Thorp, Co-founder and General Partner of Hatteras. “With HVP VI, we will continue to partner with innovative, driven entrepreneurs to launch and build world-class health care companies, many of which will be based upon leading-edge research stemming from the renowned academic centers in the southeastern U.S. In addition, we will continue to leverage our expanding national network to co-invest in promising companies in other regions.”
To support the firm’s continued growth, coincident with the closing of the new fund, Hatteras announced the promotions of Mike Dial, Ph.D., and Jeff Terrell to Partner. Dr. Dial and Mr. Terrell both joined Hatteras as analysts and have honed their respective skills as investors, board members and strategic thinkers while continuing to take on increasing responsibility.
“Mike and Jeff have proven themselves to be invaluable members of the Hatteras team,” said Robert A. Ingram, General Partner of Hatteras. “They will be key drivers in our funds’ performance going forward.”
In addition to the promotions of Dr. Dial and Mr. Terrell, Hatteras has added Ben Scruggs, Ph.D., as Associate, and Kseniya Simpson, Ph.D., as Analyst. Drs. Scruggs and Simpson earned their doctorate degrees from preeminent academic institutions Washington University in St. Louis and Yale University, respectively. Both are core members of the investment team, which has capability to analyze and add value to a range of companies solving critical, unmet medical needs.
About HVP VI
With $200 million in planned deployable capital, HVP VI will continue Hatteras’ focus on investing in compelling seed and early stage biopharmaceutical, medical device, digital health and diagnostic opportunities. HVP VI will seek to invest across the health care continuum from transformative therapy companies that address unmet medical needs for patients to disruptive technologies that change the way therapies are developed or care is provided. Successful companies in the HVP IV and V portfolios – including transformative therapy companies like G1 Therapeutics, StrideBio, Graybug Vision and NeuroTronik, Inc. and disruptive technology companies like Bivarus, Inc., Elligo Health Research and Qvella – are illustrative of the kinds of companies in which Hatteras will seek to continue to invest. To help support these high-growth companies, Hatteras has developed strong relationships with over 100 institutional co-investors around the world.
Source: Hatteras Venture Partners